Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.
Patients with moderate to severe hypertension frequently require>or=2 antihypertensives to achieve blood pressure (BP) control. The combination telmisartan/amlodipine is especially suitable for the treatment of severely hypertensive, high-risk patients, because it offers a substantial and sustained 24-h BP-lowering effect and is well tolerated in a range of patients with hypertension, who are at risk for cardiovascular events. ACCOMPLISH was the first trial to test two fixed-dose combinations (the angiotensin-converting enzyme inhibitor [ACEi] benazepril in combination with either the diuretic hydrochlorothiazide [HCTZ] or the calcium channel blocker amlodipine). It was shown that a combination including amlodipine was superior to that including HCTZ in reducing the risk of cardiovascular events and death among high-risk patients. Results of the ONTARGET study comparing telmisartan with ramipril showed that telmisartan was an equally effective alternative to ramipril and less likely to cause angioedema. The telmisartan/amlodipine combination is therefore a particularly attractive choice for difficult-to-control hypertensive patients at cardiovascular risk, including those with diabetes, or those who are obese, elderly, not controlled by amlodipine monotherapy, or who are intolerant to ACEi.
Ahrens
K
K
Institut fur Kardiovaskulare Pharmakologie und Epidemiologie, Mahlow, Germany.
Bramlage
P
P
D017311:Amlodipine / Q000009:adverse effects / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use*; D001769:Blood / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D012720:Severity of Illness Index; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D004338:Drug Combinations; C548840:telmisartan amlodipine combination; D017311:Amlodipine; D000077333:Telmisartan